{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T23:49:17Z","timestamp":1778975357916,"version":"3.51.4"},"reference-count":141,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The neonatal intensive care unit (NICU) population, especially low birth weight and critically ill neonates, is at risk of invasive Candida infections, which are associated with high mortality rates and unfavorable long-term outcomes. The timely initiation of an appropriate antifungal treatment has been demonstrated to enhance the prognosis. Factors that should be considered in the choice of an antifungal agent include the causative Candida strain, the presence and location of deep tissue infection, any previous use of antifungal prophylaxis, and the presence of implanted devices. Amphotericin B and fluconazole, the first-line drugs for neonatal candidiasis, are not always suitable due to several limitations in terms of efficacy and adverse effects. Therefore, alternative antifungals have been studied and used in neonates when conventional antifungals are ineffective or contraindicated. This narrative review aims to provide an overview of the current literature regarding the use of echinocandins in the neonatal population. The three echinocandins, micafungin, caspofungin, and anidulafungin, share characteristics that make them useful for the treatment of neonatal candidiasis, including activity against a wide range of Candida strains and Candida biofilms and a favorable safety profile.<\/jats:p>","DOI":"10.3390\/antibiotics13121209","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T08:36:32Z","timestamp":1733992592000},"page":"1209","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit"],"prefix":"10.3390","volume":"13","author":[{"given":"Niki","family":"Dermitzaki","sequence":"first","affiliation":[{"name":"Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-8673","authenticated-orcid":false,"given":"Foteini","family":"Balomenou","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Gialamprinou","sequence":"additional","affiliation":[{"name":"Second Neonatal Department and Neonatal Intensive Care Unit (NICU), \u201cPapageorgiou\u201d University Hospital, Aristotle University of Thessaloniki, 56403 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Giapros","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-0345","authenticated-orcid":false,"given":"Dimitrios","family":"Rallis","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Baltogianni","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41390-021-01842-7","article-title":"Invasive fungal infections in neonates: A review","volume":"91","author":"Weimer","year":"2022","journal-title":"Pediatr. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2022058813","DOI":"10.1542\/peds.2022-058813","article-title":"Late-Onset Sepsis Among Very Preterm Infants","volume":"150","author":"Flannery","year":"2022","journal-title":"Pediatrics"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Kelly, E., Luu, T.M., Ye, X.Y., Ting, J., Shah, P.S., and Lee, S.K. (2023). Fungal infection and neurodevelopmental outcomes at 18\u201330 months in preterm infants. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1145252"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bersani, I., Piersigilli, F., Goffredo, B.M., Santisi, A., Cairoli, S., Ronchetti, M.P., and Auriti, C. (2019). Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives. Front. Pediatr., 7.","DOI":"10.3389\/fped.2019.00375"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1542\/peds.2004-2292","article-title":"National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: Risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months","volume":"117","author":"Benjamin","year":"2006","journal-title":"Pediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Han, T., Qiu, M., Niu, X., Wang, S., Wang, F., Cao, J., Tang, S., Cheng, L., Mei, Y., and Liang, H. (2024). End-organ damage from neonatal invasive fungal infection: A 14-year retrospective study from a tertiary center in China. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09360-7"},{"key":"ref_7","unstructured":"Edwards, M., and Puopolo, K. (2024). Candida Infections in Neonates: Epidemiology, Clinical Manifestations, and Diagnosis, UpToDate. Available online: https:\/\/www.uptodate.com."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jpeds.2013.04.034","article-title":"Neurodevelopmental outcome of extremely low birth weight infants with Candida infection","volume":"163","author":"Bann","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/cid\/ciab025","article-title":"A Regulatory Review Approach for Evaluation of Micafungin for Treatment of Neonatal Candidiasis","volume":"73","author":"Taormina","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/INF.0000000000001968","article-title":"Canadian Neonatal Network Investigators. Invasive Fungal Infections in Neonates in Canada: Epidemiology and Outcomes","volume":"37","author":"Ting","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/INF.0000000000002530","article-title":"Eurocandy Study Group. Etiology and Outcome of Candidemia in Neonates and Children in Europe: An 11-year Multinational Retrospective Study","volume":"39","author":"Warris","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1093\/jpids\/piy009","article-title":"Neonatal and Pediatric Candidemia: Results from Population-Based Active Laboratory Surveillance in Four US Locations, 2009\u20132015","volume":"7","author":"Benedict","year":"2018","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/myc.13145","article-title":"Characteristics, outcome and risk factors for mortality of paediatric patients with ICU-acquired candidemia in India: A multicentre prospective study","volume":"63","author":"Chakrabarti","year":"2020","journal-title":"Mycoses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"myad010","DOI":"10.1093\/mmy\/myad010","article-title":"Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study","volume":"61","author":"Cook","year":"2023","journal-title":"Med. Mycol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Noni, M., Stathi, A., Vaki, I., Velegraki, A., Zachariadou, L., and Michos, A. (2019). Changing Epidemiology of Invasive Candidiasis in Children during a 10-Year Period. J. Fungi, 5.","DOI":"10.3390\/jof5010019"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"He, B., and Yang, Q. (2023). Updates in Laboratory Identification of Invasive Fungal Infection in Neonates. Microorganisms, 11.","DOI":"10.3390\/microorganisms11041001"},{"key":"ref_18","first-page":"45","article-title":"Updated Perspectives on the Diagnosis and Management of Neonatal Invasive Candidiasis","volume":"13","author":"Daniel","year":"2023","journal-title":"Res. Rep. Neonatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/myc.13035","article-title":"Diagnostic value of Candida mannan antigen and anti-mannan IgG and IgM antibodies for Candida infection","volume":"63","author":"Wang","year":"2020","journal-title":"Mycoses"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ferreras-Antolin, L., Borman, A., Diederichs, A., Warris, A., and Lehrnbecher, T. (2022). Serum Beta-D-Glucan in the Diagnosis of Invasive Fungal Disease in Neonates, Children and Adolescents: A Critical Analysis of Current Data. J. Fungi, 8.","DOI":"10.3390\/jof8121262"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Camp, I., Spettel, K., and Willinger, B. (2020). Molecular Methods for the Diagnosis of Invasive Candidiasis. J. Fungi, 6.","DOI":"10.3390\/jof6030101"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QCO.0b013e328343614e","article-title":"Amphotericin B in neonates: Deoxycholate or lipid formulation as first-line therapy\u2014Is there a \u2018right\u2019 choice?","volume":"24","author":"Turkova","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Akinosoglou, K., Rigopoulos, E.A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C., and Dimopoulos, G. (2024). Amphotericin B in the Era of New Antifungals: Where Will It Stand?. J. Fungi, 10.","DOI":"10.3390\/jof10040278"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/17425255.2020.1773793","article-title":"Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population","volume":"16","author":"Scott","year":"2020","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_25","first-page":"115","article-title":"Review of Fluconazole Treatment and Prophylaxis for Invasive Candidiasis in Neonates","volume":"26","author":"Hornik","year":"2021","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Carmo, A., Rocha, M., Pereirinha, P., Tom\u00e9, R., and Costa, E. (2023). Antifungals: From Pharmacokinetics to Clinical Practice. Antibiotics, 12.","DOI":"10.3390\/antibiotics12050884"},{"key":"ref_27","first-page":"20499361231161387","article-title":"Flucytosine and its clinical usage","volume":"10","author":"Sigera","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Faustino, C., and Pinheiro, L. (2020). Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010029"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14656566.2012.647685","article-title":"Invasive fungal infections during the neonatal period: Diagnosis, treatment and prophylaxis","volume":"13","author":"Tezer","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/myc.12904","article-title":"Candida auris-the growing menace to global health","volume":"62","author":"Lone","year":"2019","journal-title":"Mycoses"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Petraitiene, R., Petraitis, V., Zaw, M.H., Hussain, K., Ricart Arbona, R.J., Roilides, E., and Walsh, T.J. (2024). Combination of Systemic and Lock-Therapies with Micafungin Eradicate Catheter-Based Biofilms and Infections Caused by Candida albicans and Candida parapsilosis in Neutropenic Rabbit Models. J. Fungi, 10.","DOI":"10.3390\/jof10040293"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S604","DOI":"10.1093\/cid\/civ814","article-title":"Echinocandins: The Expanding Antifungal Armamentarium","volume":"61","author":"Petraitiene","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins-structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Chmielewska","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Mroczy\u0144ska, M., and Brillowska-D\u0105browska, A. (2020). Review on Current Status of Echinocandins Use. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050227"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections: A comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jauregizar, N., Quind\u00f3s, G., Gil-Alonso, S., Su\u00e1rez, E., Sevillano, E., and Eraso, E. (2022). Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?. J. Fungi, 8.","DOI":"10.3390\/jof8070727"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"myae065","DOI":"10.1093\/mmy\/myae065","article-title":"Comparative efficacies of the three echinocandins for Candida auris candidemia: Real world evidence from a tertiary centre in India","volume":"62","author":"Prayag","year":"2024","journal-title":"Med. Mycol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"myac008","DOI":"10.1093\/mmy\/myac008","article-title":"Emerging and future strategies in the management of recalcitrant Candida auris","volume":"60","author":"Bandara","year":"2022","journal-title":"Med. Mycol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/bcp.12025","article-title":"Antifungal agents and therapy for infants and children with invasive fungal infections: A pharmacological perspective","volume":"75","author":"Lestner","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11908-016-0549-2","article-title":"Echinocandin Resistance in Candida Species: A Review of Recent Developments","volume":"18","author":"Wiederhold","year":"2016","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3201\/eid2302.161320","article-title":"Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris","volume":"23","author":"Sherry","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/INF.0000000000002032","article-title":"Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis","volume":"38","author":"Tsekoura","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-2008-1063859","article-title":"Update on echinocandin antifungals","volume":"29","author":"Kauffman","year":"2008","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ijantimicag.2019.02.019","article-title":"Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials","volume":"53","author":"Chen","year":"2019","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_47","unstructured":"(2024, October 15). Food and Drug Administration (FDA), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021506s023lbl.pdf."},{"key":"ref_48","unstructured":"(2024, October 15). European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mycamine-epar-product-information_en.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"De Rose, D.U., Bersani, I., Ronchetti, M.P., Piersigilli, F., Cairoli, S., Dotta, A., Desai, A., Kovanda, L.L., Goffredo, B.M., and Auriti, C. (2023). Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030472"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"212608","DOI":"10.7573\/dic.212608","article-title":"Neonatal pharmacology and clinical implications","volume":"8","author":"Ruggiero","year":"2019","journal-title":"Drugs Context."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/bdd.752","article-title":"Higher clearance of micafungin in neonates compared with adults: Role of age-dependent micafungin serum binding","volume":"32","author":"Yanni","year":"2011","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.03736-14","article-title":"Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents","volume":"59","author":"Hope","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/INF.0b013e3181910e2d","article-title":"Pharmacokinetics of an elevated dosage of micafungin in premature neonates","volume":"28","author":"Smith","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.inf.0000245103.07614.e1","article-title":"The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants","volume":"25","author":"Heresi","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/clpt.2009.200","article-title":"Safety and pharmacokinetics of repeat-dose micafungin in young infants","volume":"87","author":"Benjamin","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000001996","article-title":"A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis","volume":"37","author":"Benjamin","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/bcp.13628","article-title":"Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: A randomized, open-label clinical trial","volume":"84","author":"Leroux","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/524063","article-title":"The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates","volume":"197","author":"Hope","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Parramon-Teixido, C.J., Garcia Esquerda, C., Frick, M.A., Tripodi, C., Gomez-Ganda, L., Ruiz-Campillo, C.W., and Caba\u00f1as-Poy, M.J. (2024). Case Report: Micafungin for treating Candida glabrata, urinary infection: A clinical case in a premature neonate. Front. Pediatr., 12.","DOI":"10.3389\/fped.2024.1397456"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijantimicag.2016.05.010","article-title":"Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp.","volume":"48","author":"Grau","year":"2016","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mmcr.2016.01.003","article-title":"Micafungin in the treatment of candiduria: A case series","volume":"11","author":"Kane","year":"2016","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Javorova Rihova, Z., Slobodova, L., and Hrabovska, A. (2021). Micafungin Is an Efficient Treatment of Multi Drug-Resistant Candida glabrata Urosepsis: A Case Report. J. Fungi, 7.","DOI":"10.3390\/jof7100800"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e02494-20","DOI":"10.1128\/AAC.02494-20","article-title":"High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study","volume":"65","author":"Auriti","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1093\/jac\/dkw305","article-title":"Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: A retrospective observational cohort study of the Mycoses Study Group (MSG-12)","volume":"71","author":"Chiotos","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"De Rose, D.U., Piersigilli, F., Goffredo, B.M., Danhaive, O., Dotta, A., and Auriti, C. (2021). Treatment with Micafungin in a Preterm Neonate with an Invasive Candida parapsilosis Infection after a Severe Terlipressin-Induced Skin Necrosis. Pathogens, 10.","DOI":"10.3390\/pathogens10070890"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.mycmed.2020.100968","article-title":"Comparative in vitro activities of seven antifungal drugs against clinical isolates of Candida parapsilosiscomplex","volume":"30","author":"Khodavaisy","year":"2020","journal-title":"J. Mycol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jpc.15019","article-title":"Neonatal Candida auris infection: Management and prevention strategies\u2014A single centre experience","volume":"56","author":"Chandramati","year":"2020","journal-title":"J. Paediatr. Child. Health"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1128\/AAC.01172-16","article-title":"High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis","volume":"60","author":"Auriti","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/INF.0000000000000434","article-title":"Micafungin in premature and non-premature infants: A systematic review of 9 clinical trials","volume":"33","author":"Manzoni","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/jp.2008.197","article-title":"Hepatitis associated with micafungin use in a preterm infant","volume":"29","author":"King","year":"2009","journal-title":"J. Perinatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5414\/CP202015","article-title":"Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects","volume":"52","author":"Undre","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: Review of the literature","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/14787210.2020.1794817","article-title":"Caspofungin: A review of its characteristics, activity, and use in intensive care units","volume":"18","author":"Hashemian","year":"2020","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.01027-08","article-title":"Pharmacokinetics and safety of caspofungin in older infants and toddlers","volume":"53","author":"Neely","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.00868-08","article-title":"Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age","volume":"53","author":"Macias","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","unstructured":"(2024, October 24). Food and Drug Administration (FDA), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206110lbl.pdf."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4137\/CMPed.S8016","article-title":"Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections","volume":"6","author":"Wiederhold","year":"2012","journal-title":"Clin. Med. Insights Pediatr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pedneo.2021.11.003","article-title":"Advocacy for close monitoring of caspofungin therapy in premature infants: A case report","volume":"63","author":"Marion","year":"2022","journal-title":"Pediatr. Neonatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e00248-19","DOI":"10.1128\/AAC.00248-19","article-title":"Body Surface Area-Based Dosing Regimen of Caspofungin in Children: A Population Pharmacokinetics Confirmatory Study","volume":"63","author":"Yang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/AAC.00905-10","article-title":"Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients","volume":"55","author":"Li","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jiac.2015.01.009","article-title":"Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis","volume":"21","author":"Mori","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Niu, C.H., Xu, H., Gao, L.L., Nie, Y.M., Xing, L.P., Yu, L.P., Wu, S.L., and Wang, Y. (2020). Population Pharmacokinetics of Caspofungin and Dosing Optimization in Children with Allogeneic Hematopoietic Stem Cell Transplantation. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00184"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jac\/dkz398","article-title":"A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3\u2009months of age","volume":"75","author":"Kim","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.02085-12","article-title":"Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin","volume":"57","author":"Jans","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.jp.7211637","article-title":"Caspofungin for the treatment of azole resistant candidemia in a premature infant","volume":"27","author":"Smith","year":"2007","journal-title":"J. Perinatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mycmed.2017.01.010","article-title":"Persistent Candida conglobata bloodstream infection in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin","volume":"27","author":"Ahmad","year":"2017","journal-title":"J. Mycol. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/INF.0b013e31819d1cf1","article-title":"Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant","volume":"28","author":"Natale","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/01.inf.0000200141.46957.71","article-title":"Caspofungin for refractory candidemia in neonates","volume":"25","author":"Manzar","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/sj.jp.7211380","article-title":"Experience with caspofungin in the treatment of persistent fungemia in neonates","volume":"25","author":"Natarajan","year":"2005","journal-title":"J. Perinatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jfma.2014.01.003","article-title":"Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks\u2019 gestation","volume":"113","author":"Jeon","year":"2014","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.inf.0000145408.51526.0a","article-title":"Caspofungin therapy of neonates with invasive candidiasis","volume":"23","author":"Odio","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/tropej\/fmr025","article-title":"A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants","volume":"58","author":"Mohamed","year":"2012","journal-title":"J. Trop. Pediatr."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40265-014-0227-3","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children: Clinical implications","volume":"74","author":"Autmizguine","year":"2014","journal-title":"Drugs"},{"key":"ref_98","unstructured":"(2024, October 18). European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ecalta-epar-product-information_en.pdf."},{"key":"ref_99","unstructured":"(2024, October 18). Food and Drug Administration (FDA), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021632027_S029lbl.pdf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e0016921","DOI":"10.1128\/AAC.00169-21","article-title":"Human Tissue Distribution of Anidulafungin and Micafungin","volume":"65","author":"Marx","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e00275-20","DOI":"10.1128\/AAC.00275-20","article-title":"Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex","volume":"64","author":"Marx","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/bdrb.20347","article-title":"Tissue distribution of anidulafungin in neonatal rats","volume":"95","author":"Ripp","year":"2012","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cpt.1831","article-title":"Population Analysis of Anidulafungin in Infants to Older Adults with Confirmed or Suspected Invasive Candidiasis","volume":"108","author":"Xie","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.2011.26","article-title":"Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates","volume":"89","author":"Benjamin","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.05826-11","article-title":"Anidulafungin for neonatal hematogenous Candida meningoencephalitis: Identification of candidate regimens for humans using a translational pharmacological approach","volume":"56","author":"Warn","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/INF.0000000000002568","article-title":"Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age with Invasive Candidiasis, Including Candidemia","volume":"39","author":"Roilides","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/INF.0000000000002237","article-title":"Anidulafungin A8851008 Pediatric Study Group. A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age","volume":"38","author":"Roilides","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Kriegel, C., Festag, M., Kishore, R.S.K., Roethlisberger, D., and Schmitt, G. (2019). Pediatric Safety of Polysorbates in Drug Formulations. Children, 7.","DOI":"10.3390\/children7010001"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40780-021-00208-9","article-title":"Potentially harmful excipients in neonatal medications: A multicenter nationwide observational study in Japan","volume":"7","author":"Saito","year":"2021","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Sokou, R., Palioura, A.E., Kopanou Taliaka, P., Konstantinidi, A., Tsantes, A.G., Piovani, D., Tsante, K.A., Gounari, E.A., Iliodromiti, Z., and Boutsikou, T. (2024). Candida auris Infection, a Rapidly Emerging Threat in the Neonatal Intensive Care Units: A Systematic Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061586"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e0054921","DOI":"10.1128\/AAC.00549-21","article-title":"Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis","volume":"65","author":"Gamal","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","unstructured":"(2024, October 20). Center for Diseases Control and Prevention (CDC), Available online: https:\/\/www.cdc.gov\/candida-auris\/hcp\/clinical-care\/index.html."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijmmb.2021.03.025","article-title":"Candida auris, an emerging pathogen\u2014Challenge in the survival of microprimies","volume":"39","author":"Ramya","year":"2021","journal-title":"Indian. J. Med. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Talapko, J., Juzba\u0161i\u0107, M., Matijevi\u0107, T., Pustijanac, E., Beki\u0107, S., Kotris, I., and \u0160krlec, I. (2021). Candida albicans\u2014The Virulence Factors and Clinical Manifestations of Infection. J. Fungi, 7.","DOI":"10.3390\/jof7020079"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Junqueira, J.C., and Mylonakis, E. (2023). Editorial: Candida biofilms. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1128600"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3934\/microbiol.2023025","article-title":"Biofilm: The invisible culprit in catheter-induced candidemia","volume":"9","author":"Wijaya","year":"2023","journal-title":"AIMS Microbiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e00797-18","DOI":"10.1128\/AAC.00797-18","article-title":"Echinocandin Treatment of Candida albicans Biofilms Enhances Neutrophil Extracellular Trap Formation","volume":"62","author":"Hoyer","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Malinovsk\u00e1, Z., \u010conkov\u00e1, E., and V\u00e1czi, P. (2023). Biofilm Formation in Medically Important Candida Species. J. Fungi, 9.","DOI":"10.3390\/jof9100955"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Cavalheiro, M., and Teixeira, M.C. (2018). Candida Biofilms: Threats, Challenges, and Promising Strategies. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00028"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Imbert, C., and Rammaert, B. (2018). What Could Be the Role of Antifungal Lock-Solutions? From Bench to Bedside. Pathogens, 7.","DOI":"10.3390\/pathogens7010006"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1086\/652783","article-title":"Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents","volume":"201","author":"Katragkou","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Chen, Y.N., Hsu, J.F., Chu, S.M., Lai, M.Y., Lin, C., Huang, H.-R., Yang, P.H., Chiang, M.C., and Tsai, M.H. (2022). Clinical and Microbiological Characteristics of Neonates with Candidemia and Impacts of Therapeutic Strategies on the Outcomes. J. Fungi, 8.","DOI":"10.3390\/jof8050465"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/lam.13653","article-title":"Antifungal lock therapy: An eternal promise or an effective alternative therapeutic approach?","volume":"74","author":"Majoros","year":"2022","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2022.03.010","article-title":"Catheter salvage strategies in children with central venous catheter-related or -associated bloodstream infections: A systematic review and meta-analysis","volume":"125","author":"Buonsenso","year":"2022","journal-title":"J. Hosp. Infect."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"S618","DOI":"10.1093\/cid\/civ815","article-title":"The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems","volume":"61","author":"Ghannoum","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Wagener, J., and Loiko, V. (2017). Recent Insights into the Paradoxical Effect of Echinocandins. J. Fungi, 4.","DOI":"10.3390\/jof4010005"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ijantimicag.2009.07.001","article-title":"In Vitro analysis of the occurrence of a paradoxical effect with different echinocandins and Candida albicans biofilms","volume":"34","author":"Miceli","year":"2009","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1128\/AAC.02541-12","article-title":"Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: Characterization of less common bloodstream isolates","volume":"57","author":"Simitsopoulou","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1099\/jmm.0.032235-0","article-title":"In Vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms","volume":"60","author":"Ku","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41429-018-0123-2","article-title":"Paradoxical growth effect of caspofungin on Candida spp. sessile cells not only at high drug concentrations","volume":"72","year":"2019","journal-title":"J. Antibiot"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Iosifidis, E., Papachristou, S., and Roilides, E. (2018). Advances in the Treatment of Mycoses in Pediatric Patients. J. Fungi, 4.","DOI":"10.3390\/jof4040115"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/INF.0000000000002001","article-title":"German Neonatal Network. Antifungal Treatment and Outcome in Very Low Birth Weight Infants: A Population-based Observational Study of the German Neonatal Network","volume":"37","author":"Fortmann","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/INF.0000000000002463","article-title":"Neonatal Antifungal Consumption Is Dominated by Prophylactic Use; Outcomes from the Pediatric Antifungal Stewardship: Optimizing Antifungal Prescription Study","volume":"38","author":"Irwin","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Chu, M., Lin, J., Wang, M., Liao, Z., Cao, C., Hu, M., Ding, Y., Liu, Y., and Yue, S. (2023). Restrictive Use of Empirical Antibiotics Is Associated with Improved Short Term Outcomes in Very Low Birth Weight Infants: A Single Center, Retrospective Cohort Study from China. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040741"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Zini, T., Miselli, F., D\u2019Esposito, C., Fidanza, L., Cuoghi Costantini, R., Corso, L., Mazzotti, S., Rossi, C., Spaggiari, E., and Rossi, K. (2024). Sustaining the Continued Effectiveness of an Antimicrobial Stewardship Program in Preterm Infants. Trop. Med. Infect. Dis., 9.","DOI":"10.3390\/tropicalmed9030059"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"De Rose, D.U., Ronchetti, M.P., Santisi, A., Bernaschi, P., Martini, L., Porzio, O., Dotta, A., and Auriti, C. (2024). Stop in Time: How to Reduce Unnecessary Antibiotics in Newborns with Late-Onset Sepsis in Neonatal Intensive Care. Trop. Med. Infect. Dis., 9.","DOI":"10.3390\/tropicalmed9030063"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/jpids\/piy043","article-title":"Antibiotic Stewardship in the Neonatal Intensive Care Unit: Effects of an Automatic 48-Hour Antibiotic Stop Order on Antibiotic Use","volume":"8","author":"Astorga","year":"2019","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1097\/INF.0000000000003967","article-title":"Antifungal Stewardship Programs in Children: Challenges and Opportunities","volume":"42","author":"Kourti","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.04109-14","article-title":"ARPEC Project Group. Systemic antifungal prescribing in neonates and children: Outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study","volume":"59","author":"Lestner","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Albahar, F., Alhamad, H., Abu Assab, M., Abu-Farha, R., Alawi, L., and Khaleel, S. (2023). The Impact of Antifungal Stewardship on Clinical and Performance Measures: A Global Systematic Review. Trop. Med. Infect. Dis., 9.","DOI":"10.3390\/tropicalmed9010008"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T09:14:42Z","timestamp":1760433282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":141,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["antibiotics13121209"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13121209","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}